Furthermore, the direct fusion of an anti-IL-6R that blocks further downstream signalling by inhibiting the JAK/STAT pathway responsible for the promotion of tumour growth and metastasis could provide beneficial anti-tumour properties. Here, IL6R is linked to neoplasm.